Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1Dermatologic 1CNS 1

Conditions

Prostatic Neoplasms 30Lung Neoplasms 30Carcinoma, Non-Small-Cell Lung 26Leukemia, Myeloid, Acute 25Multiple Myeloma 22Breast Neoplasms 20Lymphoma 18Carcinoma, Renal Cell 17Urinary Bladder Neoplasms 15Leukemia, Lymphocytic, Chronic, B-Cell 15Myelodysplastic Syndromes 14Lymphoma, Large B-Cell, Diffuse 14Colorectal Neoplasms 14Pancreatic Neoplasms 11Neoplasm Metastasis 11Ovarian Neoplasms 10Myeloproliferative Disorders 10Mouth Neoplasms 10Glioma 10Glioblastoma 10Burkitt Lymphoma 10Squamous Cell Carcinoma of Head and Neck 9Triple Negative Breast Neoplasms 8Sarcoma 8Rectal Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Melanoma 8Lymphoma, Non-Hodgkin 8Laryngeal Neoplasms 8Carcinoma 8

Interventions

pembrolizumab 3apatinib 3Magnetic Resonance Spectroscopy 3lenvatinib 2Specimen Handling 2Nivolumab 2Imatinib Mesylate 2Epirubicin 2Cisplatin 2Carboplatin 2Axitinib 24-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2regorafenib 1gallium 68 PSMA-11 1enfortumab vedotin 1cabozantinib 1avelumab 1anlotinib 1amivantamab 1Tretinoin 1Sunitinib 1Radiation 1Pemetrexed 1Nelfinavir 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Lutetium-177 1Lutetium 1Ipilimumab 1Glutamate Carboxypeptidase II 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Adenoid Cystic × Specimen Handling × Clear all
NCT04895735 2026-06-04

MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer

Mayo Clinic

Phase 2 Active not recruiting
45 enrolled 12 charts
Head & Neck

Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms

NCT02834013 2026-06-03

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
798 enrolled
CNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckSarcoma

Nasopharyngeal Carcinoma, Bile Duct Neoplasms, Carcinoma, Basal Cell, Adenocarcinoma, Bronchiolo-Alveolar, Adenocarcinoma, Mucinous, Carcinoma, Transitional Cell, Carcinosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Gallbladder Neoplasms, Hemangiosarcoma, Mouth Neoplasms, Paget Disease, Extramammary, Paraganglioma, Paranasal Sinus Neoplasms, Parathyroid Neoplasms, Pheochromocytoma, Pseudomyxoma Peritonei, Somatostatinoma, Thyroid Neoplasms, Vulvar Neoplasms, Desmoid Tumors, Seminoma, Carcinoma, Acinar Cell, Adrenocortical Carcinoma, Carcinoma, Endometrioid, Cholangiocarcinoma, Cystadenocarcinoma, Mucinous, Cystadenocarcinoma, Serous, Carcinoma, Giant Cell, Neurofibrosarcoma, Gestational Trophoblastic Disease, Rare Diseases, Gastrointestinal Stromal Tumors, Perivascular Epithelioid Cell Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡